Cover Image

Dipeptidyl peptidase 4 (DPP-4) inhibitors and cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM): a systematic review and meta-analysis

Abstract Background Dipeptidyl peptidase 4 (DPP-4) inhibitors are newer oral anti-diabetic agents which have been approved by the Food and Drug Administration for the treatment of patients with type 2 diabetes mellitus (T2DM). In this analysis, we aimed to systematically compare the cardiovascular o...

Full description

Saved in:

Bibliographic Details
Main Authors:	Dan Liu (Author), Biao Jin (Author), Wei Chen (Author), Peng Yun (Author)
Format:	Book
Published:	BMC, 2019-03-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence
by: Tianli Zhang, et al.
Published: (2021)

A dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, attenuates cardiac dysfunction after myocardial infarction independently of DPP-4
by: Takehiro Yamaguchi, et al.
Published: (2019)

Design, Synthesis and Biological Evaluation of Neogliptin, a Novel 2-Azabicyclo[2.2.1]heptane-Based Inhibitor of Dipeptidyl Peptidase-4 (DPP-4)
by: Ivan O. Maslov, et al.
Published: (2022)

Renoprotective Effect of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus
by: Hiroki Esaki, et al.
Published: (2017)

Risk of Cardiovascular Events and Medical Cost of Dapagliflozin and Dipeptidyl Peptidase-4 Inhibitors
by: Jong-Mi Seong, et al.
Published: (2021)

Navigating the chemical space of dipeptidyl peptidase-4 inhibitors
by: Shoombuatong W, et al.
Published: (2015)

Impact on decision making framework for medicine purchasing in Chinese public hospital decision-making: determining the value of five dipeptidyl peptidase 4 (DPP-4) inhibitors
by: Yun Bao, et al.
Published: (2021)

Bullous pemphigoid receiving a novel long‐acting dipeptidyl‐peptidase‐4 (DPP‐4) inhibitor omarigliptin in a patient with type 2 diabetes: A case report
by: Hiroshi Kasamatsu, et al.
Published: (2021)

Comparative effect of dipeptidyl-peptidase 4 inhibitors on laboratory parameters in patients with diabetes mellitus
by: Yayoi Nishida, et al.
Published: (2020)

Effect of Dipeptidyl-Peptidase 4 Inhibitors on Circulating Oxidative Stress Biomarkers in Patients with Type 2 Diabetes Mellitus
by: Elisabetta Bigagli, et al.
Published: (2020)

Suspected adverse drug reactions of the type 2 antidiabetic drug class dipeptidyl‐peptidase IV inhibitors (DPP4i): Can polypharmacology help explain?
by: Lauren Jones, et al.
Published: (2022)

Drug Repurposing: Dipeptidyl Peptidase IV (DPP4) Inhibitors as Potential Agents to Treat SARS-CoV-2 (2019-nCoV) Infection
by: Praveen P. N. Rao, et al.
Published: (2021)

Association of serum and salivary dipeptidyl peptidase-4 (DPP-4) with oral cancerous and precancerous lesions; an observational diagnostic accuracy study
by: Nayroz Abdel Fattah Tarrad, et al.
Published: (2024)

Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin
by: Capuano A, et al.
Published: (2013)

Treatment with metformin and a dipeptidyl peptidase-4 inhibitor elevates apelin levels in patients with type 2 diabetes mellitus
by: Fan YJ, et al.
Published: (2015)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
by: Chenkai Cui, et al.
Published: (2022)

Co-medications and dipeptidyl peptidase-4 inhibitors associated bullous pemphigoid,
by: Agoritsa Gravani, et al.
Published: (2022)

UNEXPECTED ADVERSE REACTIONS OF THE DRUGS OF THE GROUP OF INHIBITORS OF DIPEPTIDYL PEPTIDASE-4
by: T. V. Romanova, et al.
Published: (2018)

The Effect of Dipeptidyl Peptidase-4 Inhibitors on Macrovascular and Microvascular Complications of Diabetes Mellitus: A Systematic Review
by: Olesya M. Taylor, PharmD, BCPS, et al.
Published: (2020)

Dipeptidyl Peptidase (DPP)-IV Inhibitors with Antioxidant Potential Isolated from Natural Sources: A Novel Approach for the Management of Diabetes
by: Anand-Krishna Singh, et al.
Published: (2021)

Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy in elderly type 2 diabetes patients in Thailand
by: Permsuwan U, et al.
Published: (2016)

Pemphigoid nodularis induced by long-term use of dipeptidyl peptidase-4 inhibitors
by: Natsumi Norikawa, et al.
Published: (2023)

Dipeptidyl Peptidase-4 Inhibitor-associated Bullous Pemphigoid: Recurrence with Epitope Spreading
by: Hiroyuki Takama, et al.
Published: (2018)

Effect of Dipeptidyl Peptidase-4 Inhibitors on Bone Metabolism and the Possible Underlying Mechanisms
by: Yinqiu Yang, et al.
Published: (2017)

Dipeptidyl peptidase IV inhibitors and the risk of mycobacterial pulmonary infections in type 2 diabetes mellitus
by: Cheng-Yi Wang, et al.
Published: (2023)

α-Amylase and dipeptidyl peptidase-4 (DPP-4) inhibitory effects of Melicope latifolia bark extracts and identification of bioactive constituents using in vitro and in silico approaches
by: Alexandra Quek, et al.
Published: (2021)

Comparison of serum amylase level between dipeptidyl peptidase-4 inhibitor and GLP-1 analog administration in patients with type 2 diabetes mellitus
by: Junichi Okada, et al.
Published: (2019)

Neuroprotective effects of dipeptidyl peptidase 4 inhibitor on Alzheimer's disease: a narrative review
by: Xin Jiang, et al.
Published: (2024)

Rurality is associated with lower likelihood of dipeptidyl peptidase 4 inhibitor use for treatment intensification
by: Danielle K. Nagy, et al.
Published: (2024)

Revolutionizing Treatment Strategies for Autoimmune and Inflammatory Disorders: The Impact of Dipeptidyl-Peptidase 4 Inhibitors
by: Rahim K, et al.
Published: (2024)

Association between Dipeptidyl Peptidase-4 Inhibitor Prescription and Erythropoiesis-Stimulating Agent Hyporesponsiveness in Hemodialysis Patients with Diabetes Mellitus
by: Takeshi Hasegawa, et al.
Published: (2021)

Safety of dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
by: Katharina Doni, et al.
Published: (2022)

Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes
by: Christina S. Kwon, et al.
Published: (2018)

In silico studies of Ruellia tuberosa L. compounds as aldose reductase, dipeptidyl peptidase 4, and α-glucosidase inhibitors against type 2 diabetes mellitus
by: Ekowati Retnaningtyas, et al.
Published: (2024)

Comparison of Efficacy of Dipeptidyl Peptidase‐4 Inhibitors and Sodium‐Glucose Co‐Transporter 2 Inhibitors Between Japanese and Non‐Japanese Patients: A Meta‐Analysis
by: Yuka Ito, et al.
Published: (2020)

Design, synthesis and anti-diabetic activity of piperazine sulphonamide derivatives as dipeptidyl peptidase-4 inhibitors
by: Swarna Bharathi Kalli, et al.
Published: (2022)

Dipeptidyl Peptidase-4 inhibitors use in type II diabetic patients in a tertiary hospital
by: Woh Yon Mak, et al.
Published: (2020)

A Comprehensive Review and Perspective on Natural Sources as Dipeptidyl Peptidase-4 Inhibitors for Management of Diabetes
by: Sibhghatulla Shaikh, et al.
Published: (2021)

Soluble Dipeptidyl Peptidase-4 Induces Fibroblast Activation Through Proteinase-Activated Receptor-2
by: Shih-Yi Lee, et al.
Published: (2020)

Head-to-Head Comparison of the Hypoglycemic Efficacy and Safety Between Dipeptidyl Peptidase-4 Inhibitors and α-Glucosidase Inhibitors in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials
by: Zhaoliang Li, et al.
Published: (2019)